← Back to headlines
Valneva Outlines 2026 Revenue Guidance, Pfizer Targets Lyme Decisions
Valneva has outlined its 2026 revenue guidance between $145 million and $160 million, while Pfizer aims to make decisions regarding its Lyme disease initiatives within the next 12 months.
14 Aug, 02:30 — 14 Aug, 02:30
Sources
Showing 1 of 1 sources
Related Stories
US Army Awards $2.2 Billion for Nuclear Microreactors at Five Bases
17m ago
Oil Prices Decline on Prospects of Diplomatic Talks to Ease Middle East Supply Disruptions
38m ago
FSSAI Issues Food Safety Notices to Premier Delhi Hotels Ahead of BRICS Summit
55m ago
South Korea Central Bank Raises Rates to 3%, Upgrades Growth Forecast
55m ago